The standard treatments for venous diseases of the lower limb include compression bandaging and stockings as well as surgical removal of varicose veins. There are a number of conditions in which these conventional treatments are ineffective, particularly in the management of leg ulceration. Drug treatments for healing venous leg ulcers have yet to be developed to the stage of good clinical efficacy, but these may assist in the management of patients. Flavonoid drugs have been widely used in the management of the symptoms of venous disease for many years and have recently been studied in some detail to assess their effects on the microcir culation. Work in animal models of ischemia-reperfusion show that MPFF (micronized purified flavonoid fraction) modulates leukocyte adhesion and prevents endothelial damage. Similar biochemical effects have been observed in patients with venous disease and may explain the efficacy of this drug in the management of edema and other symptoms of venous disease. There is clinical evidence that MPFF modifies venous leg ulcer healing.
Abenhaim L., Clément D., Norgren L., et al, for the International Task Force: The management of chronic venous disorders of the leg: An evidenced-based report of an international task forcePhlebology14 (suppl)1:1-26, 1999.
3.
Scriven JM, Hartshorne T., Thrush AJ, et al: Role of saphenous vein surgery in the treatment of venous ulcerationBr J Surg85:781-784, 1998.
4.
Shami SK, Sarin S., Cheatle TR, et al: Venous ulcers and the superficial venous systemJ Vasc Surg17:487-490, 1993.
5.
Ghauri AS, Nyamekye I., Grabs AJ, et al: Influence of a specialised leg ulcer service and venous surgery on the outcome of venous leg ulcersEur J Vasc Endovasc Surg16:238-244, 1998.
6.
Franks PJ, Oldroyd MI, Dickson D., et al: Risk factors for leg ulcer recurrence: A randomized trial of two types of compression stockingAge Ageing24:490-494, 1995.
7.
Lyseng-Williamson K., Perry C.: Micronized purified flavonoid fraction. A review of its use in chronic venous insufficiency, venous ulcers and hemorrhoidsDrugs63:71-100, 2003.
8.
Coleridge Smith PD, Thomas P., Scurr JH, et al: Causes of venous ulceration: A new hypothesisBr Med J296:1726-1172, 1988 .
9.
Weissman G., Smolen JE, Korchak HM: Release of inflammatory mediators from stimulated neutrophilsN Engl J Med303:27-34, 1980.
10.
Babior BM: Oxidants from phagocytes: Agents of defense and destructionBlood64:959-966, 1984.
11.
Linas SL, Shanley PF, Whittenburg D., et al : Neutrophils accentuate ischemia-reperfusion injury in isolated perfused rat kidneysAm J Physiol255:F728-F735, 1988.
12.
Braide M., Blixt A., Bagge U.: Leukocyte effects on the vascular resistance and glomerular filtration of the isolated rat kidney at normal and low flow ratesCirc Shock20:71-80, 1986.
13.
Engler RL, Dahlgren MD, Peterson MA, et al: Accumulation of polymorphonuclear leukocytes during three hour myocardial ischemiaAm J Physiol251: H93-H100, 1986.
14.
Moyses C., Cederholm-Williams SA, Michel CC: Haemoconcentration and the accumulation of white cells in the feet during venous stasisInt J Microcirc Clin Exp5:311-320, 1987.
15.
Thomas Prs, Nash GB, Dormandy JA: White cell accumulation in the dependent legs of patients with ambulatory venous hypertension: A possible mechanism for trophic changes in the skinBr Med J296: 1693-1695, 1988 .
16.
Vanscheidt W., Kresse O., Hach-Wunderle V., et al: Left ulcer patients: No decreased fibrinolytic response but white cell trapping after venous occlusion of the upper limbPhlebology7:92-96, 1992.
17.
Shields DA, Andaz S., Sarin S., et al: Neutrophil activation in experimental venous hypertensionPhlebologie46:687-689, 1993.
18.
Saharay M., Shields DA, Porter JB, et al: Leukocyte activity in the microcirculation of the leg in patients with chronic venous diseaseJ Vasc Surg26:265-273, 1997.
19.
Shields DA, Andaz SK, Sarin S., et al: Plasma elastase in venous diseaseBr J Surg81:1496-1499, 1994.
20.
Shields DA, Andaz S., Abeysinghe RD, et al : Plasma lactoferrin as a marker of white cell degranulation in venous diseasePhlebology9:55-58, 1994.
21.
Saharay M., Shields DA, Georgiannos SN, et al : Endothelial activation in patients with chronic venous diseaseEur J Vasc Endovasc Surg15:342-349, 1998.
22.
Ciuffetti G. , Lombardini R., Pasqualini L., et al: Circulating leucocyte adhesion molecules in chronic venous insufficiencyVasa28:156-159, 1999.
23.
Garner RC, Garner JV, Gregory S., et al: Comparison of the absorption of micronized (Daflon 500® mg) and nonmicronized 14C-Diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry and liquid scintillation countingJ Pharm Sci91:32-40, 2002.
24.
Laurent R., Gilly R., Frileux C.: Clinical evaluation of a venotropic drug in man. Example of Daflon 500 mgInt Angiol7(suppl 2) :39-43, 1988.
25.
Jantet G., and the RELIEF study group: Chronic venous insufficiency: Worldwide results of the RELIEF studyAngiology53:T1-T12, 2002.
26.
Juteau N., Bakri F., Pomies JP, et al: The human saphenous vein in pharmacology: Effect of a new micronized flavonoidic fraction (Daflon 500 mg) on norepinephrine-induced contractionInt Angiol14(suppl 1):8-13, 1995.
27.
Ibegbuna V. , Nicolaides AN, Sowade O., et al: Venous elasticity after treatment with Daflon 500 mgAngiology48:45-49, 1997.
28.
Cotonat A., Cotonat J.: Lymphagogue and pulsatile activities of Daflon 500 mg on canine thoracic lymph ductInt Angiol8(suppl 4):15-18, 1989.
29.
Gargouil YM , Perdrix L., Chapelain B., et al: Effects of Daflon 500 mg on bovine vessels contractilityInt Angiol8(suppl4):19-22, 1989.
30.
McHale NG, Hollywood MA: Control of lymphatic pumping: Interest of Daflon 500 mgPhlebology9(suppl 1):23-25, 1994.
31.
Behar A., Lagrue G., Cohen-Boulakia F., et al: Study of capillary filtration by double labelling I131 albumin and Tc99m red cells. Application to the pharmacodynamic activity of Daflon 500 mgInt Angiol7(suppl 2):35-38, 1988.
32.
Galley P., Thiollet M.: A double-blind, placebo-controlled trial of a new venoactive flavonoid fraction (S 5682) in the treatment of symptomatic capillary fragilityInt Angiol12:69-72, 1993.
33.
Friesenecker B., Tsai AG, Intaglietta M.: Cellular basis of inflammation, oedema and the activity of Daflon 500 mgInt J Microcirc15:17-21, 1995.
34.
Friesenecker B., Tsai AG, Intaglietta M.: Cellular basis of inflammation, oedema and the activity of Daflon 500 mgInt J Microcirc: Clin Exp15(suppl 1):17-21, 1995.
35.
Bouskela E. , Cyrino Fzga, Lerond L.: Micronization enhances the protective effect of purified flavonoid fraction on postischemic microvascular injury in the hamster cheek pouchInt Angiol20(suppl 1): 19, 2001.
36.
Takase S., Delano FA, Lerond L., et al: Inflammation in chronic venous insufficiency: Is the problem insurmountable ?J Vasc Res36(suppl 1):3-10, 1999.
37.
Takase S., Delano FA, Lerond L., et al: The inflammatory reaction during venous hypertension in the ratMicrocirculation7:41-52, 2000.
38.
Guilhou JJ, Dereure O., Marzin L., et al: Efficacy of Daflon 500 mg in venous leg ulcer healing: A double-blind, randomized, controlled versus placebo trial in 107 patientsAngiology48:77-85, 1997.
39.
Coleridge Smith PD: The drug treatment of chronic venous insufficiency and venous ulceration In: Handbook of Venous Disorders. Guidelines of the American Venous Forum, ed. by Gloviczki P, Yao JST. London: Arnold, 2001, pp 309-321.
40.
Glinski W., Chodynicka B., Roszkiewicz J., et al : The beneficial augmentative effect of micronised purified flavonoid fraction (MPFF) on the healing of leg ulcers : An open, multicentre, controlled, randomised trialPhlebology14:151-157, 1999.
41.
Roztócil K. , Śtvrtinová V., Strejćek J.: Efficacy of a 6-month treatment with Daflon 500 mg in patients with venous leg ulcers associated with chronic venous insufficiencyInt Angiol22:24-31, 2003.
42.
Shoab SS, Porter J., Scurr JH, et al: Endothelial activation response to oral micronised flavonoid therapy in patients with chronic venous disease—a prospective studyEur J Vasc Endovasc Surg17:313-318, 1999.
43.
Shoab SS, Porter J., Scurr JH, et al: Effect of oral micronized purified flavonoid fraction treatment on leukocyte adhesion molecule expression in patients with chronic venous disease: A pilot studyJ Vasc Surg31:456-461, 2000.
